Original protocol used in research article:
Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II
Molecular Genetics and Metabolism Reports, Apr 18, 2021; DOI:
10.1016/j.ymgmr.2021.100758